These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18470643)

  • 1. PEGylated adenovirus for targeted gene therapy.
    O'Riordan CR; Song A
    Methods Mol Biol; 2008; 434():133-60. PubMed ID: 18470643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates.
    Lanciotti J; Song A; Doukas J; Sosnowski B; Pierce G; Gregory R; Wadsworth S; O'Riordan C
    Mol Ther; 2003 Jul; 8(1):99-107. PubMed ID: 12842433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
    Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
    J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of PEGylated adenovirus vector with targeting ligand.
    Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
    Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses.
    Mok H; Palmer DJ; Ng P; Barry MA
    Mol Ther; 2005 Jan; 11(1):66-79. PubMed ID: 15585407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells.
    Oh IK; Mok H; Park TG
    Bioconjug Chem; 2006; 17(3):721-7. PubMed ID: 16704210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor.
    Bonsted A; Engesaeter BØ; Høgset A; Maelandsmo GM; Prasmickaite L; D'Oliveira C; Hennink WE; van Steenis JH; Berg K
    J Gene Med; 2006 Mar; 8(3):286-97. PubMed ID: 16342300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.
    Espenlaub S; Wortmann A; Engler T; Corjon S; Kochanek S; Kreppel F
    J Gene Med; 2008 Dec; 10(12):1303-14. PubMed ID: 18837065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy.
    Yao XL; Yoshioka Y; Ruan GX; Chen YZ; Mizuguchi H; Mukai Y; Okada N; Gao JQ; Nakagawa S
    Biomacromolecules; 2012 Aug; 13(8):2402-9. PubMed ID: 22746837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.
    Romanczuk H; Galer CE; Zabner J; Barsomian G; Wadsworth SC; O'Riordan CR
    Hum Gene Ther; 1999 Nov; 10(16):2615-26. PubMed ID: 10566889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus.
    Park JW; Mok H; Park TG
    Biochem Biophys Res Commun; 2008 Feb; 366(3):769-74. PubMed ID: 18083120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus.
    Kanerva A; Zinn KR; Peng KW; Ranki T; Kangasniemi L; Chaudhuri TR; Desmond RA; Wang M; Takayama K; Hakkarainen T; Alfthan H; Stenman UH; Curiel DT; Hemminki A
    Gene Ther; 2005 Jan; 12(1):87-94. PubMed ID: 15385953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization.
    Lee GK; Maheshri N; Kaspar B; Schaffer DV
    Biotechnol Bioeng; 2005 Oct; 92(1):24-34. PubMed ID: 15937953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.
    Ogawara K; Rots MG; Kok RJ; Moorlag HE; Van Loenen AM; Meijer DK; Haisma HJ; Molema G
    Hum Gene Ther; 2004 May; 15(5):433-43. PubMed ID: 15144574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From gene therapy to virotherapy for ovarian cancer.
    Stoff-Khalili MA; Dall P; Curiel DT
    Minerva Ginecol; 2004 Dec; 56(6):503-14. PubMed ID: 15729203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic targeting strategies for adenovirus.
    Noureddini SC; Curiel DT
    Mol Pharm; 2005; 2(5):341-7. PubMed ID: 16196486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adenovirus mediated angiostatin gene therapy for ovarian cancer: experiment with nude mice].
    Jia CR; Yang SY; Han SY; Sun L
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(31):2204-8. PubMed ID: 19080673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF2-targeted adenoviral vectors for systemic and local disease.
    Sosnowski BA; Gu DL; D'Andrea M; Doukas J; Pierce GF
    Curr Opin Mol Ther; 1999 Oct; 1(5):573-9. PubMed ID: 11249664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro.
    Chillón M; Lee JH; Fasbender A; Welsh MJ
    Gene Ther; 1998 Jul; 5(7):995-1002. PubMed ID: 9813671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo restoration of RhoB expression leads to ovarian tumor regression.
    Couderc B; Pradines A; Rafii A; Golzio M; Deviers A; Allal C; Berg D; Penary M; Teissie J; Favre G
    Cancer Gene Ther; 2008 Jul; 15(7):456-64. PubMed ID: 18340357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.